These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 2999367)

  • 1. Technetium thyroid uptake ratios in pediatric Graves disease.
    Duck SC; Sty J
    J Pediatr; 1985 Dec; 107(6):905-9. PubMed ID: 2999367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prediction of remission in Graves' disease after thionamide therapy by technetium-99m early uptake].
    Misaki T; Dokoh S; Koh T; Shimbo S; Hidaka A; Iida Y; Kasagi K; Konishi J
    Kaku Igaku; 1991 Feb; 28(2):157-61. PubMed ID: 1711131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the factors associated with Tc-99m pertechnetate uptake in thyrotoxicosis and graves' disease.
    Kidokoro-Kunii Y; Emoto N; Cho K; Oikawa S
    J Nippon Med Sch; 2006 Feb; 73(1):10-7. PubMed ID: 16538017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of remission in Graves' disease treated with long-term carbimazole therapy: evaluation of technetium-99m thyroid uptake and TSH concentrations as prognostic indicators.
    Prakash R
    Eur J Nucl Med; 1996 Feb; 23(2):118-22. PubMed ID: 8925844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of (99m)Tc-pertechnetate thyroid imaging on radioactive iodine uptake.
    Guo N; Yang K; Lin YS; Wang T
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2014 Jun; 36(3):267-70. PubMed ID: 24997818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inappropriate suppression of thyrotropin during medical treatment of Graves disease in childhood.
    Sills IN; Horlick MN; Rapaport R
    J Pediatr; 1992 Aug; 121(2):206-9. PubMed ID: 1640284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Graves' disease: thyroid function and immunologic activity.
    Gossage AA; Crawley JC; Copping S; Hinge D; Himsworth RL
    J Nucl Med; 1982 Nov; 23(11):973-7. PubMed ID: 6290623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrence of hyperthyroidism in multinodular goiter after long-term drug therapy: a comparison with Graves' disease.
    van Soestbergen MJ; van der Vijver JC; Graafland AD
    J Endocrinol Invest; 1992 Dec; 15(11):797-800. PubMed ID: 1283983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistent Graves' hyperthyroidism despite rapid negative conversion of thyroid-stimulating hormone-binding inhibitory immunoglobulin assay results: a case report.
    Ohara N; Kaneko M; Kitazawa M; Uemura Y; Minagawa S; Miyakoshi M; Kaneko K; Kamoi K
    J Med Case Rep; 2017 Feb; 11(1):32. PubMed ID: 28162094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thyroid blood flow and uptake of technetium-99m pertechnetate in Graves' disease.
    Sekulić V; Rajić M; Vlajković M; Ilić S; Bogićević M; Antić S; Dimić D
    Hell J Nucl Med; 2006; 9(3):173-6. PubMed ID: 17160158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thyroid suppression test and outcome of hyperthyroidism treated with antithyroid drugs and triiodothyronine.
    Yamamoto M; Igarashi T; Kimura S; Tsukamoto S; Togawa K; Ogata E
    J Clin Endocrinol Metab; 1979 Jan; 48(1):72-7. PubMed ID: 581766
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison between peak systolic velocity of the inferior thyroid artery and technetium-99m pertechnetate thyroid uptake in differentiating Graves' disease from thyroiditis.
    Malik SA; Choh NA; Misgar RA; Khan SH; Shah ZA; Rather TA; Shehjar F; Laway BA
    Arch Endocrinol Metab; 2019; 63(5):495-500. PubMed ID: 31482952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Thyroid gland hemiagenesis with Graves' disease].
    Mikosch P; Gallowitsch HJ; Kresnik E; Lind P
    Nuklearmedizin; 1999; 38(1):35-7. PubMed ID: 9987780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Graves disease with midline ectopic and bifid pyramidal lobes on pertechnetate thyroid scintigraphy.
    Shinto A; Bandopadhyay A; Selvakumar J
    Clin Nucl Med; 2009 Jan; 34(1):31-2. PubMed ID: 19092381
    [No Abstract]   [Full Text] [Related]  

  • 15. Serial occurrence of two types of postpartum thyroid disorders. Usefulness of Tc-99m pertechnetate uptake.
    Misaki T; Miyamoto S; Kasagi K; Mori T; Konishi J
    Clin Nucl Med; 1996 Jun; 21(6):460-2. PubMed ID: 8744180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EVALUATION OF QUANTITATIVE THYROID SCINTIGRAPHY FOR DIAGNOSIS AND STAGING OF DISEASE SEVERITY IN CATS WITH HYPERTHYROIDISM: COMPARISON OF THE PERCENT THYROIDAL UPTAKE OF PERTECHNETATE TO THYROID-TO-SALIVARY RATIO AND THYROID-TO-BACKGROUND RATIOS.
    Peterson ME; Guterl JN; Rishniw M; Broome MR
    Vet Radiol Ultrasound; 2016 Jul; 57(4):427-40. PubMed ID: 27062212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two cases of Graves' disease with presentation of unilateral diffuse uptake of radioisotopes.
    Sakata S; Fuwa Y; Goto S; Fukui M; Yuasa H; Takuno H; Sarui H; Matsui I; Ogawa T; Sasano N
    J Endocrinol Invest; 1993 Dec; 16(11):903-7. PubMed ID: 8144868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of anti-thyroid drug treatment duration on thyroid gland microvessel density and intraoperative blood loss in patients with Graves' disease.
    Erbil Y; Giriş M; Salmaslioglu A; Ozluk Y; Barbaros U; Yanik BT; Kapran Y; Abbasoglu SD; Ozarmagan S
    Surgery; 2008 Feb; 143(2):216-25. PubMed ID: 18242338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is thyroid scintigraphy necessary before I-131 therapy for hyperthyroidism? Concise communication.
    Ripley SD; Freitas JE; Nagle CE
    J Nucl Med; 1984 Jun; 25(6):664-7. PubMed ID: 6327946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thyrotoxic Graves' disease with normal thyroidal technetium-99m pertechnetate uptake.
    Ikekubo K; Hino M; Ito H; Koh T; Ishihara T; Kurahachi H; Kasagi K; Hidaka A; Mori T
    Ann Nucl Med; 1990 Jul; 4(2):43-8. PubMed ID: 2171608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.